Show simple item record

Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.

dc.contributor.authorRaymond, E
dc.contributor.authorNiccoli, P
dc.contributor.authorCastellano, D
dc.contributor.authorValle, Juan W
dc.contributor.authorHammel, P
dc.contributor.authorRaoul, J
dc.contributor.authorVinik, A
dc.contributor.authorBang, Y
dc.contributor.authorLee, S
dc.contributor.authorBorbath, I
dc.contributor.authorBohas, C
dc.contributor.authorMetrakos, P
dc.contributor.authorSmith, D
dc.contributor.authorChen, J
dc.contributor.authorSeitz, J
dc.contributor.authorPatyna, S
dc.contributor.authorHuang, X
dc.contributor.authorIshak, J
dc.contributor.authorFaivre, S
dc.contributor.authorRuszniewski, P
dc.date.accessioned2016-08-10T10:06:17Z
dc.date.available2016-08-10T10:06:17Z
dc.date.issued2016
dc.identifier.citationSunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. 2016, 34(4) J Clin Oncolen
dc.identifier.urihttp://hdl.handle.net/10541/618150
dc.language.isoenen
dc.titleSunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBeaujon Hospital, Clichy, Franceen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record